Literature DB >> 16197817

Can Doppler time domain analysis of microembolic signals discriminate between gaseous and solid microemboli in patients with left ventricular assist device?

Nils H Thoennissen1, Achim Allroggen, Ralf Dittrich, Martin Ritter, Christof Schmid, Hans H Scheld, E Bernd Ringelstein, Darius G Nabavi.   

Abstract

OBJECTIVE: Microembolic signals (MES) can be detected by transcranial Doppler sonography (TCD). To identify gaseous microemboli the inhalation of oxygen is an established method in patients with prosthetic heart valves. Time domain analysis of sample volume length (SVL) and of frequency modulation showed promising results in the discrimination between solid and gaseous microemboli. We investigated whether these time domain analyses allow the discrimination of different types of microemboli in patients with the non-pulsatile DeBakey left ventricular assist device (LVAD).
MATERIALS AND METHODS: Repeated unilateral detection of MES was performed by TCD in 20 patients supported with DeBakey LVAD. Each monitoring session consisted of 20 minutes without and 20 minutes with inhalation of 100% oxygen (6 l/min). A total of 500 MES, detected with (n=250) or without (n=250) the supply of oxygen, were randomly chosen for offline analysis. The SVL (in cm) was calculated by duration and velocity of the MES measured in the time domain mode. Additionally, frequency modulation of MES was classified into three main types: Without modulation (type I), with gradual changes (type II) and with rapid changes (type III).
RESULTS: With oxygen supply, both prevalence (26.4% versus 36.2%, p<0.01) and mean counts of MES per hour (49+/-293 versus 108+/-550, p<0.001) significantly declined compared with the MES load while breathing room air. There was no significant difference in the SVL of MES under oxygen (0.85+/-0.38 cm) compared with those without oxygen delivery (0.92+/-0.37 cm, p=0.6). Furthermore, no significant differences were noted for the MES frequency modulation types in time domain analysis with regard to oxygen supply.
CONCLUSIONS: The reduction of MES under oxygen delivery confirms the gaseous nature in a substantial number of circulating microemboli produced by the DeBakey LVAD. However, SVL and frequency modulation of MES did not appear to provide valuable information regarding the structural nature of the underlying microembolic material.

Entities:  

Mesh:

Year:  2005        PMID: 16197817     DOI: 10.1179/016164105X39950

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  5 in total

1.  Evidence-based used, yet still controversial: the arterial filter.

Authors:  Filip De Somer
Journal:  J Extra Corpor Technol       Date:  2012-03

2.  Assessing Cerebrovascular Hemodynamics Using Transcranial Doppler in Patients with Mechanical Circulatory Support Devices.

Authors:  Kara R Melmed; Konrad H Schlick; Brenda Rinsky; Oana M Dumitrascu; Oksana Volod; Mani Nezhad; Matthew M Padrick; Carmelita Runyan; Francisco A Arabia; Jaime D Moriguchi; Patrick D Lyden; Shlee S Song
Journal:  J Neuroimaging       Date:  2020-02-10       Impact factor: 2.486

3.  Microemboli monitoring by trans-cranial doppler in patient with acute cardioemboliogenic stroke due to atrial myxoma.

Authors:  Gregory Telman; Orit Mesica; Efim Kouperberg; Oved Cohen; Gil Bolotin; Yoram Agmon
Journal:  Neurol Int       Date:  2010-06-21

4.  Online Measurement of Microembolic Signal Burden by Transcranial Doppler during Catheter Ablation for Atrial Fibrillation-Results of a Multicenter Trial.

Authors:  Christian von Bary; Thomas Deneke; Thomas Arentz; Anja Schade; Heiko Lehrmann; Sabine Fredersdorf; Dobri Baldaranov; Lars Maier; Felix Schlachetzki
Journal:  Front Neurol       Date:  2017-04-05       Impact factor: 4.003

5.  Stroke Incidence and Impact of Continuous-Flow Left Ventricular Assist Devices on Cerebrovascular Physiology.

Authors:  William K Cornwell; Amrut V Ambardekar; Tomio Tran; Jay D Pal; Luis Cava; Justin Lawley; Takashi Tarumi; Christy L Cornwell; Keith Aaronson
Journal:  Stroke       Date:  2019-02       Impact factor: 7.914

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.